Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
Holding COGT?
Track your performance easily
COGT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.67 - $12.61
Previous Close$9.08
Volume277.68K
Average Volume (3M)1.10M
Market Cap
$1.01B
Enterprise Value$683.09M
Total Cash (Recent Filing)$335.52M
Total Debt (Recent Filing)$17.83M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Mar 18, 2025EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding110,461,729
10 Day Avg. Volume1,563,585
30 Day Avg. Volume1,096,745
Standard Deviation0.67
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)3.88
Price to Sales (P/S)1053.46
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue719.05
Enterprise Value/Gross Profit719.05
Enterprise Value/Ebitda-2.79
Forecast
1Y Price Target
$16.57Price Target Upside80.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Cogent Biosciences News
PremiumCompany Announcements
Cogent Biosciences Reports Progress in Clinical Trials and Financial StandingBulls Say, Bears Say
Bulls Say
Clinical TrialsPatients treated with 100 mg bezuclastinib had a reduction in the MS2D2 TSS of 49.1% vs 21.1% for placebo at 12 weeks.
Financial PerformanceCogent has a strong cash position of $346M which can fund operations into late 2026.
Pipeline DevelopmentBezuclastinib’s high selectivity should reduce off target toxicity and allow for a cleaner profile that should enable higher dosing and potentially improved efficacy.
Bears Say
Competitive LandscapeBoth OKI-219 and Scorpion's STX-478 appear to have greater in vivo anti-tumor efficacy compared to CGT6297.
Financial PerformancePrice target is lowered to $15 based on higher expenses.
Market SentimentShort interest of 10.0% suggests a significant level of skepticism or bearish sentiment among investors.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.67 and its highest was $12.61 in the past 12 months.
What is Cogent Biosciences’s market cap?
Currently, no data Available
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Mar 18, 2025 which is in 117 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Nov 12, 2024. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.566 by -$0.074.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -$0.59.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 110,461,730 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.566. Following the earnings report the stock price went down -0.192%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Among the largest hedge funds holding Cogent Biosciences’s share is Fairmount Funds Management Llc. It holds Cogent Biosciences’s shares valued at 67M.
---
Cogent Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.57 (80.21% Upside)
$16.57 (80.21% Upside)
Hedge Fund Trend
Decreased
By 450.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.7%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.58%
12-Months-Change
Fundamentals
Return on Equity
-78.47%
Trailing 12-Months
Asset Growth
8.04%
Trailing 12-Months
Company Description
Cogent Biosciences
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
---
COGT Stock 12 Month Forecast
Average Price Target
$16.57
▲(80.21% Upside)
Technical Analysis
Best Analysts Covering COGT
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+8.77%
reiterated a buy rating 18 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +8.77% per trade.
---